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Abstract 
Context: Adrenal venous sampling (AVS) is the key test for subtyping primary aldosteronism 
(PA), but its interpretation varies widely across referral centers and this can adversely affect 
the management of PA patients.  
Objectives: To investigate in a real life study the rate of bilateral success, identification of 
unilateral aldosteronism and blood pressure outcomes in PA subtyped by AVS. 
Design and settings: in a retrospective analysis of the largest international registry of 
individual AVS data (AVIS-2 study) we investigated how different cut-off values of the 
selectivity (SI) and lateralization index (LI) affected rate of bilateral su cess, identification of 
unilateral aldosteronism and blood pressure outcomes.  
Results: AVIS-2 recruited 1625 individual AVS studies performed between 2000 and 2015 in 
19 tertiary referral centers. Under unstimulated conditions, the rate of biochemically confirmed 
bilateral AVS success progressively decreased with increasing SI cut-offs; furthermore, with 
currently used LI cut-offs the rate of identified unilateral PA leading to adrenalectomy was as 
low as < 25%.  A within-patient pairwise comparison of 402 AVS performed both under 
unstimulated and cosyntropin-stimulation conditions showed that cosyntropin increased the 
confirmed rate of bilateral selectivity for SI cut-offs ≥ 2.0, but with reduced lateralization rates 
(p < 0.001). Post-adrenalectomy outcomes were not improved by use of cosyntropin or more 
restrictive diagnostic criteria.  
Conclusion: Commonly used SI and LI cut-offs are associated with disappointingly low rates 
of biochemically defined AVS success and identified unilateral PA. Evidence-based protocols 
entailing less restrictive interpretative cut-offs might optimize the clinical use of this costly and 
invasive test. 
 
Précis  
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Restrictive selectivity and lateralization criteria for adrenal vein sampling lead to low rates of 
success and identification of unilateral forms of primary aldosteronism, without outcome 
advantages. 
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INTRODUCTION 
Primary aldosteronism (PA) is incorrectly regarded as a rare condition, despite evidence 
showing that it is the most common cause of endocrine hypertension.(1-4) Failure to identify 
and subtype PA at an early stage leaves a multitude of patients exposed to life-long 
hyperaldosteronism, and thus to a high risk of cardiovascular events, particularly atrial 
fibrillation, as shown in both retrospective and prospective studies.(5-8)  
In the work-up of PA patients, the subtyping is a fundamental step, because patients with a 
unilateral form, mostly aldosterone-producing adenoma (APA) and unilateral adrenal 
hyperplasia,(9,10) benefit from laparoscopic adrenalectomy to obtain definitive correction of 
the hyperaldosteronism and often cure of arterial hypertension. Conversely, patients with 
bilateral PA, predominantly bilateral adrenal hyperplasia (also known as idiopathic 
hyperaldosteronism), require life-long medical treatment with a mineralocorticoid receptor 
antagonist (MRA), often in combination with multiple other antihypertensive agents.  
To distinguish between unilateral and bilateral PA, all current guidelines advocate use of 
adrenal vein sampling (AVS),(11,12) a technically demanding test where success is defined as  
bilateral selectivity, i.e. adequate sampling of both adrenal veins. Confirmation of selectivity 
also serves to minimize the impact of two potential confounders when ascertaining 
lateralization of aldosterone excess: the degree of proximity of the catheter’s tip to the adrenal 
cortex, and dilution effect from blood in accessory veins or inferior vena cava.  
The criteria to define selectivity and lateralization remain, however, quite variable even at 
major tertiary centers where AVS is performed on a regular basis, as shown by data from a 
large international survey (AVIS-1),(13) and expert consensus reports.(14,15) This 
heterogeneity in interpretation can have a profound effect on the clinical decision-making, and 
thus on the usefulness of AVS.  
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The Adrenal Vein sampling International Study (AVIS)-2 was planned after completion of 
AVIS-1(13) with the aim of creating a large international registry of individual AVS data. The 
results of this study regarding patient outcomes, i.e. correction of aldosteronism and rate of 
cured/improvement of arterial hypertension are reported elsewhere (16): not only did they 
provide a snapshot of what occurs in real-life and highlight the general outcome benefit of 
AVS-guided surgical decision-making, but also demonstrated the inconsistencies in AVS use 
and their profound clinical implications.(16) Based on those findings, in this study we wished 
to explore the potential impact and usefulness of more standardized AVS interpretation criteria 
on management of PA patients. Hence, we herein report on: i) the potential rate of selective 
(confirmed successful) AVS studies, ii) the potential rate of unilateral PA suitable for 
adrenalectomy; iii) the post adrenalectomy blood pressure outcomes as a function of the AVS 
protocol and of commonly advocated diagnostic cut-offs for the indexes defining selectivity 
(SI) and lateralization (LI).  
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METHODS 
The study rationale, design, center recruitment, inclusion/exclusion criteria, population 
characteristics and outcome analysis of AVIS-2 were reported in a separate paper (16) and are 
recapitulated in the Supplemental Methods(17). All procedures were carried out according to 
the Helsinki Declaration. The protocol of the study was approved by the Ethics Committee of 
both the coordinating center and the participating centers. 
In brief, de-identified biochemical data from individual AVS studies were entered in a 
dedicated web-based platform (https://fm.dmcs.unipd.it) by local investigators who entered the 
units of measure as per local practice to avoid any conversion errors. The data collection form 
is shown in the Supplemental material(17). Post-hoc harmonization to Conventional Units was 
undertaken in the final database. After database locking, data were checked for internal 
consistency and standing queries were clarified with centers’ lead investigators. AVS indices 
were defined as previously reported and per guidelines(11,18,19): i) the Selectivity Index (SI) 
is the ratio between plasma cortisol concentration (PCC) in the adrenal vein (AV) and 
(infrarenal) inferior vena cava (IVC) and estimates the correct positioning of catheters in the 
adrenal vein [PCCAV/PCCIVC]; ii) the “central/peripheral ratio”, originally introduced by 
Espiner E.A. et al (20) and renamed by some of us (GR, GPR) “relative aldosterone secretion 
index” (RASI) (21), is the ratio between the plasma aldosterone concentration (PAC) in each 
adrenal vein (AV) and inferior vena cava (IVC) divided by the degree of selectivity, i.e. dilution, 
and identifies the contribution of the culprit (dominant) and non-culprit (non-dominant) adrenal 
to aldosterone secretion [(PACAV/PCCAV)/(PACIVC/PCCIVC)]; in the non-dominant side it is 
equivalent to the so-called  “contralateral suppression index”; iii) the Lateralization Index (LI) 
is the ratio between the higher and the lower RASI [or, after simplification: (PAC dominant 
AV/PCC dominant AV)/(PAC non-dominant AV/PCC non-dominant AV)] and measures the imbalance in 
aldosterone secretion between the adrenal glands. 
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The blood pressure outcomes at follow-up were categorized according to predefined classes as 
cure ,defined as normal blood pressure without any antihypertensive medication, no 
improvement, defined as lack of blood pressure reduction and/or need for increased number 
and/or dose of antihypertensive medications, and improvement, the latter split into marked and 
mild (Supplemental Table 1)(17). These classes are basically equivalent to those currently used 
(complete, partial and absent clinical success) after publication of the clinical outcome (PASO) 
classification.(22) Data were analyzed per protocol according to the original classification, but 
also by collapsing into a joint definition of partial clinical success the marked and mild 
improvement, in order to allow for a swift comparison with studies that used the PASO criteria, 
and also for a broad generalization of the conclusions.  
The diagnostic and outcome impact of different interpretative rules for SI and LI on AVS data 
obtained with different AVS protocols (non-stimulated, i.e. basal, or stimulated) was explored 
in the entire cohort. Cut-offs used for the analysis were those recommended by guidelines 
(11,23) and/or endorsed by expert consensus documents.(14,15)  
A paired, within-patient, within-AVS comparison was conducted for cases with available pre 
and post-cosyntropin results. ROC (receiver operator characteristic) curve analyses were 
performed to assess the erformance of SI interpretation rules obtained under unstimulated 
conditions (SI unstimulated) using the post-cosyntropin selectivity data, defined as a SI cosyntropin 
cut-off = 5.0, as reference standard. This was based on current use and evidence of a clear-cut 
bimodal separation after cosyntropin (please see results)(17). The Youden index was used to 
identify the optimal cut-off value for SI unstimulated, i.e. the best combination of sensitivity and 
specificity using post-cosyntropin-ascertained selectivity as classification criterion. The value 
identified in this analysis (see Results) was included as one of the cut-offs for which the 
diagnostic/outcome performance was explored. 
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A sensitivity analysis of the impact of cosyntropin was also performed by repeating the paired 
comparisons and excluding each individual center stepwise. 
The values of SI, LI, and RASI, which showed a skewed distribution at the Kolmogorov-
Smirnov test, are reported as median and interquartile range (IQR) and compared across groups 
with non-parametric Wilcoxon test. The frequency of categorical variables was analyzed with 
Pearson’s χ2; McNemar’s test was used for comparison between different diagnostic criteria 
within the same population. Significance was set at p<0.05. SPSS for Mac (vers. 25 for Mac, 
IBM-SPSS Bologna, Italy), GraphPad, Prism (vers. 8.1.1 for Mac, GraphPad Software, La Jolla 
California USA), and MedCalc (MedCalc Software Ostend Belgium, vers. 15.8) softwares 
were used for the statistical analysis.  
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RESULTS 
Study population 
The whole database included 1820 individual AVS datasets from consecutive patients studied 
in 19 centers (Supplemental Table 2)(17). However, to focus upon current AVS practice, the 
oldest AVS datasets were excluded and the analysis was limited to 1625 individual cases 
performed from 2000 to 2015 (Figure 1). The clinical/demographic features of the PA patient 
population were reported in detail elsewhere (16) and are recapitulated in the Supplemental 
Table 3 (17).  
Overall, AVS datasets were available in 1274 patients under unstimulated conditions and in 
865 cases after pharmacologic stimulation (742 with cosyntropin, (85.8%), and 123 with 
metoclopramide). In 402 patients (24.7% of the total) both unstimulated and cosyntropin-
stimulated AVS was performed during the same procedure. This furnished the opportunity for 
a paired within-patient-within-AVS comparison. Metoclopramide was only used in one center, 
as already described(19,24); the results obtained with metoclopramide are reported here simply 
for comparison with the cosyntropin-stimulated AVS.  
In 1004/1274 of AVS performed under unstimulated conditions, in 637/742 after stimulation 
and in 317/402 AVS after both unstimulated and cosyntropin-stimulated conditions, post-AVS 
outcome data were available. 
Rate of confirmed, successful AVS selectivity at different biochemical SI cut-off 
definitions 
Unstimulated AVS 
The analysis of the success rate of adrenal catheterization under unstimulated conditions 
showed that increasingly higher biochemical definitions of the SI cut-off up to 5.0 resulted in 
a progressive fall in the rate of confirmed selective studies on each side and bilaterally (Figure 
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2 and Supplemental Table 4)(17). With the most stringent cut-off of 5.0, only 38.3% of the 
studies were deemed bilaterally selective; however the rate rose to 52.4% and 67.3% with the 
commonly used cut-off values of 3.0 and 2.0, respectively.  
Post-cosyntropin stimulated AVS 
In contrast to the drop in confirmed success observed with increasingly restrictive SI cut-off 
definitions under unstimulated conditions or during metoclopramide stimulation (Figure 2 and 
Supplemental Figure 1)(17), use of more stringent SI cut-off definitions had less impact upon 
determination of catheterization success when measured after cosyntropin infusion. Despite 
more stringent interpretation criteria, the proportion of AVS deemed successful decreased only 
by 9%, i.e. from 90.2% at an SI cut-off of 1.1, to 81.3% at 5.0.  
Importantly, the currently recommended SI cut-off for cosyntropin-stimulated AVS of 5.0 
(11,15) was associated with a higher rate of bilaterally successful AVS procedures than with 
using any SI cut-off definitions  2.0 under unstimulated conditions (Figure 2 and 
Supplemental Table 4)(17).  
Use of intraprocedural cortisol assay 
The intra-procedural rapid cortisol assay (IRCA) was used to confirm AVS selectivity under 
unstimulated conditions only in two centers for a total of 178 patients; it was associated with 
higher rates of selectivity at each SI cut-off value (Supplemental Table 5)(17). 
Comparison of the IRCA cohort with cosyntropin-stimulated AVS showed a similar rate of 
bilateral selectivity for low SI cut-offs and a better performance of the latter only at SI cut-off 
values  3.0 (Supplemental Table 5)(17).  
Comparison of unstimulated vs stimulated AVS: determination of the optimal 
unstimulated SI cut-off  
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The within-patient, within-AVS pairwise comparison of unstimulated and post-cosyntropin 
data confirmed increased values of the SI and rate of bilateral selectivity after stimulation 
(Figure 3). Notably, the SI values after cosyntropin (Supplemental Figure 2) showed a bimodal 
distribution, i.e. a clear separation of biochemically successful and non-successful studies, 
demarcated by the post-cosyntropin SI cut-off definition of 5.0, already in common use.(11,15)  
We used this value as reference for sampling success in a ROC curve analysis to explore the 
diagnostic performance of unstimulated SI values in this cohort. In general, SI values 
calculated from unstimulated measurements provided a reasonable accuracy in defining 
catheterization success (AUC 0.756 (0.724-0.785), p < 0.0001 vs the identity line AUC of 0.50). 
The Youden Index value of 1.4 from unstimulated measurements generated the highest 
combined accuracy, with 92% sensitivity and 62% specificity (Figure 3, Supplemental Table 
6)(17). When applied to the entire AVIS-2 database this definition offered a rate of successful 
selectivity under unstimulated conditions similar to that of a post-cosyntropin SI ≥ 5.0, 
regardless of IRCA being used or not (Figure 2, Supplemental Table 5)(17). Results were 
identical when we used a post-cosyntropin SI cut-off definition of 4.0 (15). 
Impact of biochemical diagnostic indices on the diagnosis of unilateral disease and 
adrenalectomy  
Identification of unilateral or bilateral aldosterone excess is possible only after confirmation of 
technical AVS success according to SI measures. We therefore assessed the rate of patients 
who could be deemed to have unilateral disease, defined by LI cut-off definitions ranging from 
2.0 to 5.0,(11,14,15) in concert with SI cut-off definitions of 1.4, 2.0, and 3.0 for unstimulated 
measurements, and 5.0 for post-cosyntropin values. This showed that the rate of lateralization 
among bilaterally successful studies, dropped significantly with adoption of higher SI cut-off 
definitions and with each unit increase in LI cut-off definition (Figure 4 top panel, 
Supplemental Table 7 and Supplemental Figure 3)(17). With commonly used biochemical 
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definitions under unstimulated and cosyntropin-stimulated conditions, i.e. ‘SI ≥ 2.0 + LI ≥ 3.0’ 
and ‘SI ≥ 5.0 + LI ≥ 4.0’, the proportion of patients deemed to have unilateral disease was 
39.8% and 36.6%, respectively, (p = 0.174 for comparison). It increased to 55.6% (p < 0.001) 
with less stringent definitions of unstimulated SI and/or LI, i.e. a SI ≥ 1.4 definition for 
selectivity combined with a cut-off of 2.0 for lateralization.  
Importantly, there was a lower rate of patients submitted to adrenalectomy after application of 
more stringent definitions for unilateral disease, to a nadir of less than 25% with an 
interpretative SI ≥ 3.0 and LI  4.0 (Supplemental Table 7)(17). However, the proportion of 
patients referred for adrenalectomy among those with AVS evidence of unilateral disease was 
higher with more restrictive criteria for lateralization, suggesting more physicians’ confidence 
in results that meet the stricter definitions (Figure 4 top panel and Supplemental Table 7)(17). 
Impact of cosyntropin use upon the determination of unilateral disease  
A pair-wise comparison of the bilaterally successful AVS under both unstimulated and 
cosyntropin-stimulated conditions showed a highly significant (p<0.001) decrease of the LI 
values between baseline and post-cosyntropin, a finding confirmed in the sub-cohort of those 
who had a unilateral form of PA unambiguously established by biochemical cure at follow-up 
post-adrenalectomy (n=149/402). Hence, after cosyntropin stimulation, notwithstanding the 
higher rate of bilaterally successful AVS studies, a lower proportion of patients was judged to 
have a unilateral form of PA (Figure 4 top panel and Supplemental Table 7)(17). 
By calculating the relative aldosterone secretion (RASI) to assess the contribution of the culprit 
and non-culprit adrenal to the LI value,(19-21)  we could clarify that the LI decreased because 
of a more prominent drop of RASI in the dominant than the non-dominant side (Table 1). This 
fall was specific to cosyntropin, as it did not occur during metoclopramide stimulation 
(Supplemental Figure 4)(17). A sensitivity analysis performed by stepwise elimination of each 
individual center showed similar results (Supplemental Table 8)(17).  
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In line with these findings and regardless of the LI definition used, the number of cases judged 
to be unilateral post-cosyntropin decreased significantly compared to the rate determined by 
unstimulated AVS measures (Table 2). Accordingly, the proportion of PA patients with 
lateralized AVS results under unstimulated conditions, and post-cosyntropin AVS results 
indicating bilateral disease, increased and could exceed 30% depending on the diagnostic 
criteria used (grey shaded cells, Table 2).  
Impact of diagnostic cut-off definitions on clinical management and blood pressure 
outcome  
The rate of patients referred to surgery decreased in accordance with the propensity of 
individual centers to trust more restrictive LI cut-off definitions of unilateral disease or results 
from cosyntropin-stimulated AVS (Figure 4 top panel). However, the relative distribution of 
blood pressure outcomes (cure, improvement and no improvement) was remarkably similar 
despite different diagnostic criteria or protocols used (Figure 4 bottom panel; supplemental 
Table 9)(17).  A borderline-significant shift from mild to marked within the class improvement 
was observed with cosyntropin.  However, this occurred at the cost of a much lower rate of 
adrenalectomies out of the selective (successful) AVS studies. Importantly, in the “paired 
measurement” cohort with apparent unilateral disease determined under unstimulated 
conditions, but no lateralization post-cosyntropin, only a minority of the patients received 
adrenalectomy (Supplemental Table 10)(17), possibly due to physicians’ perceived diagnostic 
uncertainty. While this limited the statistical power of this post-adrenalectomy outcome sub-
analysis, it is worth emphasizing that all such patients showed at least improvement.  
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DISCUSSION 
Thus far, the performance of AVS protocols and interpretations for defining procedural 
success and lateralization has only been examined in relatively small PA cohorts with limited 
geographical representation. We have now reported the performance of widely used SI and 
LI cut-off definitions and AVS protocols for the identification of unilateral forms of PA in 
the largest international registry of individual AVS studies. These results confirm and 
explain, at least in part, the disappointingly low rates of surgical cure of hypertension 
obtained in the AVIS-2 study by using local and stringent criteria for the interpretation of 
AVS in real-life clinical practice.(16) 
By examining the selectivity rate as a function of the SI cut-off definitions recommended by 
expert consensus under unstimulated conditions,(14,15) we report that approximately one 
third of PA patients submitted to AVS would not have gained any diagnostic benefit: even 
with a more lenient SI cut-off definition of 2.0 more than 20% of AVS were judged to be 
non-selective (Figure 2). With a more stringent definition, originally endorsed by the 2008 
Endocrine Society guidelines (23) and still used in many centers,(15) this rate of “failed” 
AVS was even higher, confirming previous observations from a smaller study.(18) 
The second important finding relates to the use of use of cosyntropin (synthetic 
adrenocorticotropic hormone) stimulation, which has become popular by virtue of its ability 
to generate higher SI values, thus confirming technical success in sampling. Cosyntropin can 
maximize the step-up of cortisol between the inferior vena cava (a surrogate for cortisol 
concentration in peripheral blood) and each adrenal vein. Moreover, it minimizes stress-
induced steroid fluctuations and any factitious gradients during sequential (non-simultaneous) 
AVS. The present results confirmed that cosyntropin infusion can increase the apparent AVS 
success rate when using very stringent SI cut-off definitions (Supplemental Figures 1, 4)(17); 
the known secretagogue effect of cosyntropin on cortisol and the selective secretagogue 
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effect of metoclopramide on aldosterone(21) can explain these findings, as suggested also by 
previous single-center studies.(18,25)  
More importantly, the AVIS-2 registry comprised the largest collection of AVS studies 
performed under both unstimulated and cosyntropin-stimulated conditions in the same patient 
during the same AVS procedure. As such, it offered a unique opportunity for a paired 
comparison of both selectivity and lateralization rates achieved with the two protocols. This 
within-patient and within-AVS analysis revealed a bimodal distribution of SI values post-
cosyntropin, with a discriminating level corresponding to the commonly used post-
cosyntropin SI cut-off definition of 5.0 (Figure 3 and Supplemental Figure 2)(17). Thus, even 
after stimulation and notwithstanding the aforementioned effect of cosyntropin on the SI, a 
subset of patients still showed non-successful results, indicating that cosyntropin stimulation 
cannot resolve true catheterization failure due to inadequate catheter’s positioning and/or 
unfavorable adrenal vein anatomy. The latter is not rare, as it has been documented in 
approximately 15% of PA patients.(26,27)  
By using the post-cosyntropin selectivity as a reference, we found that the unstimulated SI 
definition that offered the best combination of sensitivity and specificity was ≥ 1.4 (Fig 3, 
Suppl. Table 6)(17). This definition corresponds to a rate of bilaterally selective cases similar 
to that achieved using the post-cosyntropin SI ≥ 5.0 or ≥ 4.0. These findings, along with a 
substantial loss of diagnostically usable AVS studies (Figure 2) represent, in our view, a 
compelling argument against use of stringent SI definitions when measured under 
unstimulated conditions. The proposal of using less restrictive definitions is also supported by 
the lack of improvement in clinical outcomes with the use of more restrictive criteria (Figure 
4). 
The third main finding of the study was that only a minority of the PA patients submitted to 
AVS (from one fifth to one third, depending on the combination of currently recommended 
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restrictive SI and LI cut-off definitions) could be eventually referred for unilateral 
adrenalectomy with currently recommended SI and LI criteria. This low rate is consistent 
with the rate of AVS-guided adrenalectomy seen in AVIS-2 (31.9%), when the diagnosis was 
based on the criteria used at each center.(16)  
Overall, the low rates of biochemically defined apparent success, unilateral diagnoses, and 
referral for surgery may question the usefulness of a test that, besides being costly and 
invasive, is supposed to identify candidates for adrenalectomy. However, by applying an 
estimate of hypertension cure rate equal to that seen in the subset of patients who received 
AVS-guided adrenalectomy in AVIS-2 (16), i.e. 40%, to all those identified as likely affected 
by a unilateral form following less restrictive criteria (Figure 3), the rate of patients cured 
based on AVS results would double, from 1 in every 8 (16) to approximately 1 in every 4.  
The increased rate of bilateral catheterization success provided by cosyntropin in the 
majority, albeit not all patients, could not resolve this disappointingly low diagnostic AVS 
“yield”, in that the serious drawback of cosyntropin was a consistent drop in the lateralization 
index, as a result of a greater decrease of the relative aldosterone secretion index in the culprit 
than the contralateral side (Table 1). This drop, already observed in smaller studies,(25,28) 
may have led to judging up to 32% of PA patients as having a bilateral disease despite 
evidence of lateralization under unstimulated conditions. It may also justify the borderline-
significant shift from mild to marked improvement observed with cosyntropin and likely due 
to a preselection of the most florid phenotypes. Unfortunately, the higher rate of 
adrenalectomy among patients identified as unilateral PA after cosyntropin stimulation than 
under unstimulated sampling suggests that clinicians used to put higher confidence in post-
cosyntropin measures. On the contrary, our data conclusively disprove the contention that 
cosyntropin stimulation would increase the accuracy of AVS for identifying unilateral PA by 
maximizing the secretion of aldosterone from an APA (or other unilateral forms of PA), one 
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of the original premises for using cosyntropin: overall, cosyntropin did not result in higher 
rates of cure or better hard outcomes (Figure 4).  
Some limitations must be acknowledged along with the strengths of the AVIS-2 study, as 
discussed elsewhere.(16)   It should be acknowledged that, unlike for the surgically-curable 
unilateral PA, there is still no gold-standard for the diagnosis of bilateral adrenal hyperplasia.  
Accordingly, in order to standardize AVS performance, we felt to be of utmost importance to 
explore the clinical outcomes associated with currently-recommended AVS diagnostic 
criteria and to compare them with sets of criteria homogeneously applied to the entire cohort, 
regardless of center-specific preferences. 
It might be argued that the observational design and lack of pre-defined criteria to establish 
definitions of AVS success and lateralization, which were left to participating centers, can be 
main limitations of AVIS-2.  In truth, these can represent, major strengths of this study, as 
they allowed gathering information of use of AVS in real-life clinical practice.  Additional 
considerable strengths are a pre-defined protocol for prospective data acquisition and the 
comprehensive collection of individual biochemical data from the largest worldwide multi-
center cohort of subtyped PA patients.  
In summary, this study showed that the full diagnostic potential of AVS is largely unrealized, 
even in major referral centers with research expertise.  The use of cosyntropin during AVS, 
while increasing the rate of studies judged to be successful, resulted in decreased 
lateralization, thus masking true unilateral disease in a considerable proportion of cases.  It is 
likely that cosyntropin allows identification of only the most severe PA phenotypes,(21) thus 
explaining why it did not prove superior to a simpler CT scan-only approach in an outcome-
based randomized trial.(29)  Hence, based on data from the largest collection of AVS results 
generated from around the world, we recommend unstimulated AVS as the optimal AVS 
protocol, together with the adoption of more lenient diagnostic criteria (e.g. SI > 1.4) in 
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concert with expert clinical assessment and other predictors of unilateral disease.  The use of 
the rapid intra-procedural assays and/or of markers of selectivity that have a higher adrenal-
to-peripheral blood step-up than cortisol, such as metanephrines or androstenedione,(30-32) 
can be promising strategies to improve the clinical yield of AVS and subsequent patient 
outcomes. 
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FIGURE LEGENDS 
Figure 1. Study population. The flow-chart illustrates the distribution of the patients across 
AVS protocols. In grey, AVS performed under both unstimulated and cosyntropin-stimulated 
conditions. 
Figure 2. Rate of selectivity as a function of different SI values (definitions). The left panel 
(empty symbols) shows results under unstimulated conditions (n = 1274); the right panel 
(closed symbols) shows cosyntropin-stimulated AVS (n = 742) results. Use of increasingly 
stringent SI cut-off definitions resulted in a progressive fall in the rate of diagnostic studies 
under unstimulated conditions, but to a much lower extent under cosyntropin stimulation. 
Please note that a definition of selectivity by SIcosyntropin ≥ 5.0 performed better than any 
SIunstimulated cut-off ≥ 2.0.  * = p < 0.001 for SIcosyntropin = 5.0 vs SIunstimulated = 2.0-5.0. 
Figure 3. Impact of cosyntropin on SI and identification of optimal unstimulated SI. The 
left panel shows paired comparison of SI values in the left and right side obtained under 
unstimulated and post- cosyntropin conditions in 402 patients who were submitted to 
unstimulated and cosyntropin- stimulated AVS during the same procedure. Medians and 
interquartile ranges are shown on top. Closed symbols in the unstimulated plots correspond to 
values that were judged to be  unsuccessful, i.e. below < 5.0, post-cosyntropin. Right panel: 
ROC curve of unstimulated SI values performed using as golden reference a post-cosyntropin 
SI ≥ 5.0. Please note that the optimal cut-off for unstimulated SI,  i.e. Youden index, resulted 
to be 1.4, which corresponded to a 92% sensitivity and a 62% specificity.  
Figure 4. Lateralization, adrenalectomy and blood pressure outcomes according to 
different sets of diagnostic criteria.  
Top panel: rate of lateralization, adrenalectomy, and outcomes in the all patients referred to 
AVS under unstimulated and cosyntropin-stimulated conditions with available clinical 
outcome data (n = 880/1004 and 580/637, respectively), as a function of set of diagnostic 
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criteria. Those currently recommended are identified by the top bar, while a more lenient set 
(SI > 1.40 and LI > 2.0) based on the above paired-analysis results is shown at the extreme left 
(grey box). The empty side bar for every set shows the corresponding bilateral selectivity 
(success) rate. Filled bars indicate adrenalectomized patients, with rates of post-surgical cure, 
improvement and no improvement in shades of grey (legend at bottom). The rate of patients 
fulfilling the same set of homogeneous criteria for selectivity and lateralization but not 
submitted to surgery are indicated by the superimposed dashed bars. Please note the similar 
rate of bilateral selectivity at an unstimulated SI > 1.4 and at a post-cosyntropin SI > 5.0, but 
the lower rate of ascertained lateralization and adrenalectomy if a post-cosyntropin SI > 5.0 
were used. 
Bottom panel: The rate of cure, improvement and no improvement among patients who 
underwent adrenalectomy meeting the sets of criteria described above, i.e. the filled bars from 
top panel, were remarkably similar across sets. This indicates that use of more restrictive 
definitions of success and unilateral disease is associated with more patients denied potentially 
curative surgery (absolute numbers shown on top of each bar) but no better outcomes.  
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Figure 1 
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Figure 2 
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Figure 3 
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Figure 4 
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Table 1: paired comparison of relative aldosterone secretion index (RASI) by side and 
lateralization index (LI) between unstimulated and post-cosyntropin conditions  
 
 
Paired comparison in the subcohort of patients with bilaterally selective AVS on both non-stimulated 
(unstimulated) and post cosyntropin conditions (n = 402). PA = primary aldosteronism. Data presented as 
median (interquatile range). *SI ≥ 2.0 was used for definition of unstimulated LI; SI ≥ 5.0 was used for 
definition of post-cosyntropin LI.  Results are consistent across different SI cutoff values (not shown). Wilcoxon 
test; significance set at p < 0.05. 
  
 Whole cohort Unilateral PA 
Indexes Unstimulated 
Post 
cosyntropin 
%Δ 
RASI 
(median) 
p Unstimulated 
Post 
cosyntropin 
%Δ 
RASI 
(median) 
p 
RASI         
Dominant 
side  
7.26  
(2.79-13.00) 
3.93  
(2.71-5.32) 
- 42.0 % < 
0.001 
8.41  
(5.88-10.90) 
4.25  
(2.76-6.69) 
- 93.2 % < 
0.001 
Non-
dominant side 
1.00  
(0.47-2.34) 
1.25  
(0.34-2.33) 
- 2.6 % ns 0.52  
(0.26-1.04) 
0.37  
(0.19-0.89) 
-2.5 % 0.020 
LI* 
3.81  
(1.73-20.40) 
2.52  
(1.41-10.80) 
- < 
0.001 
17.71  
(3.87-33.28) 
9.43  
(3.18-19.84) 
- < 
0.001 
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Table 2: Diagnostic discrepancy between paired unstimulated and cosyntropin-
stimulated AVS results 
 
Cosyntropin-stimulated 
SI ≥ 5.0 
LI ≥ 3.0 P 
McNemar 
LI ≥ 4.0 P 
McNemar Lat BIlat Lat Bilat 
U
n
st
im
u
la
te
d
 
S
I 
≥
 1
.4
 LI ≥ 2.0 
Lat 118 (43.9) 74 (27.5) 
< 0.001 
106 (39.4) 86 (32.0) 
< 0.001 
Bilat 12 (4.5) 65 (24.2) 6 (2.2) 71 (26.4) 
LI ≥ 3.0 
Lat 112 (41.6) 43 (16) 
0.002 
102 (37.9) 53 (19.7) 
< 0.001 
Bilat 18 (6.7) 96 (35.7) 10 (3.7) 104 (38.7) 
LI ≥ 4.0 
Lat - - 
- 
91 (33.8) 38 (14.1) 
0.037 
Bilat - - 21 (7.8) 119 (44.2) 
S
I 
≥
 2
.0
 LI ≥ 2.0 
Lat 93 (42.3) 65 (29.5) 
< 0.001 
83 (37.7) 75 (34.1) 
< 0.001 
Bilat 8 (3.6) 54 (24.5) 3 (1.4) 59 (26.8) 
LI ≥ 3.0 
Lat 88 (40.0) 39 (17.7) 
0.001 
80 (36.4) 47 (21.4) 
< 0.001 
Bilat 13 (5.9) 80 (36.4) 6 (2.7) 87 (39.5) 
LI ≥ 4.0 
Lat - - 
- 
71 (32.3) 32 (14.5) 
0.020 
Bilat - - 15 (6.8) 102 (46.4) 
S
I 
≥
 3
.0
 LI ≥ 2.0 
Lat 68 (44.4) 42 (27.5) 
< 0.001 
62 (40.5) 48 (31.4) 
< 0.001 
Bilat 4 (2.6) 39 (25.5) 2 (1.3) 41 (26.8) 
LI ≥ 3.0 
Lat 64 (41.8) 25 (16.3) 
0.005 
59 (38.6) 30 (19.6) 
< 0.001 
Bilat 8 (5.2) 56 (36.6) 5 (3.3) 59 (38.6) 
LI ≥ 4.0 
Lat -  
 
52 (34.0) 19 (12.4) 
ns 
Bilat -  12 (7.8) 70 (45.8) 
Paired diagnostic comparison in the subcohort of patients with bilaterally selective AVS on both unstimulated 
and post cosyntropin conditions (n = 402). Data presented as n (%), according to use of different diagnostic 
criteria. Lat = AVS results suggesting lateralization according to corresponding diagnostic cut-off values; Bilat 
= AVS results suggesting bilateral PA according to corresponding diagnostic cut-off values. Baseline LI cutoff 
≥ 4.0 was not compared with post cosyntopin LI cutoff ≥ 3.0 because there is no published evidence of any 
center using a more stringent approach under unstimulated conditions. McNemar test; significance set at p < 
0.05.  
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